Clinical Drug Investigation

, Volume 10, Issue 4, pp 228–234 | Cite as

48-Hour Continuous Intragastric pH Fluctuation During Lansoprazole Administration Every Other Day

  • Yoshihiro Yamamoto
  • Shuichi Sezai
  • Shin Sakumbayashi
  • Masanori Hirano
  • Hiroshi Oka
Clinical Pharmacodynamics


The inhibitory effect on acid secretion of lansoprazole administered every other day in comparison with cimetidine was investigated in this study. Drugs and dosages were assigned to patients with peptic ulcer as follows: cimetidine 800 and 400mg daily; lansoprazole 30mg every other day. The patients’ intragastric pH was continuously measured, and the time at or above pH 4 (pH 4 holding time) was assessed. Total measurement time and night-time pH 4 holding times were 48.4 ± 3.7% and 56.1 ± 5.7%, respectively, with cimetidine 800mg; 33.7 ± 4.9% and 51.1 ± 7.3%, respectively, with cimetidine 400mg; and 66.1 ±6.1 % and 67.9 ± 5.6%, respectively, with lansoprazole every other day, revealing a significantly more powerful acid suppression in the lansoprazole than in the cimetidine groups. In addition, according to continuous 48-hour intragastric pH measurements, the pH 4 holding time during lansoprazole treatment days was significantly longer than on nontreatment days. Changes in patients’ blood gastrin levels over 48 hours while taking lansoprazole every other day revealed slightly higher values, depending on the time period, but 86% of the patients had fasting gastrin levels of 160 ng/L or less. When lansoprazole was administered every other day, the pH 4 holding time differed between the two days, and gastrin elevation was smaller. We suggest that lansoprazole every other day seems to be pharmacologically capable of being used just for peptic ulcer maintenance therapy.


Cimetidine Omeprazole Lansoprazole Drug Invest Gastrin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer; a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120–7PubMedCrossRefGoogle Scholar
  2. 2.
    Burget WD, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcer? Gastroenterology 1990; 99: 345–51PubMedGoogle Scholar
  3. 3.
    Yamamoto Y, Sakurabayashi S, Sezai S, et al. Evaluation of therapeutic efficiency in gastric ulcer — the effect of acid secretory inhibition and gastric emptying time. Ther Res 1993; 14: 1403–8Google Scholar
  4. 4.
    Chiverton SG, Hunt RH. Relationship between inhibition of acid secretion and healing of peptic ulcers. Scand J Gastroenterol 1989; 24 Suppl. 166: 43–7CrossRefGoogle Scholar
  5. 5.
    McCullough AJ, Graham DY, Knuff TE, et al. Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. Gastroenterology 1989; 97: 860–6PubMedGoogle Scholar
  6. 6.
    Cooperative study group. Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial. Gut 1990; 31: 653–6CrossRefGoogle Scholar
  7. 7.
    McFarland RJ, Bateson MC, Green RB, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990; 98: 278–83PubMedGoogle Scholar
  8. 8.
    Yamamoto Y, Hirano M. The role of acid suppression in treating peptic ulcer. Proc Jap Soc Gast Sec Res 1994; 26: 77–80Google Scholar
  9. 9.
    Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988; 23: 1259–66PubMedCrossRefGoogle Scholar
  10. 10.
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion. Digestion 1986; 35: 42–55PubMedCrossRefGoogle Scholar
  11. 11.
    Ekman L, Hansson E, Havu N, et al. Toxicological studies on omeprazole. Scand J Gastroenterol 1985; 20 Suppl. 108: 53–70Google Scholar
  12. 12.
    Baak LC, Jansen MJ, Biemond I, et al. Weekend treatment with 20 and 40mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens. Gut 1991; 32: 977–82PubMedCrossRefGoogle Scholar
  13. 13.
    Lauritsen K, Andersen BN, Laursen LS, et al. Omeprazole 20mg three days a week and 10mg daily in prevention of duodenal ulcer relapse. Gastroenterology 1991; 100: 663–9PubMedGoogle Scholar
  14. 14.
    Satoh H, Inatomi N, Nagaya H, et al. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 1989; 248: 806–15PubMedGoogle Scholar
  15. 15.
    Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 1990; 252: 1289–95PubMedGoogle Scholar
  16. 16.
    Yamamoto Y, Sakurabayashi S, Sezai S, et al. Problem and significance of 24-hr continuous measurement of intragastric pH. Gastroenterol Endosc 1993; 35: 2432–7Google Scholar
  17. 17.
    Delchier JC, Roudot-Thoraval F, Stanescu L, et al. Maintenance of intragastric pH>4 with famotidine in duodenal ulcer patients: factors influencing drug requirements. Gut 1994; 35: 750–4PubMedCrossRefGoogle Scholar
  18. 18.
    Takeda M, Iwakin C, Demura H, et al. Fundamental and clinical investigation of gastrin RIA kit II. Clin Endocrinol 1993; 31: 1123–8Google Scholar
  19. 19.
    Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75PubMedCrossRefGoogle Scholar
  20. 20.
    Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305–11PubMedGoogle Scholar
  21. 21.
    Biemond I, Klinkenberg-Knol EC, Lamers CBHW, et al. Serum pepsinogens after interruption of long-term maintenance therapy with omeprazole in patients with reflux esophagitis. Dig Dis Sci 1993; 38: 932–6PubMedCrossRefGoogle Scholar
  22. 22.
    Yamamoto Y, Sezai S, Sakurabayashi S, et al. Omeprazole versus cimetidine in the treatment of gastric ulcers. Optimal duration of acid suppression. Drug Invest 1994; 8: 377–82Google Scholar
  23. 23.
    Hewson EG, Yeomans ND, Angus PW, et al. Effect of ‘weekend therapy’ with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients. Gut 1988; 29: 1715–20PubMedCrossRefGoogle Scholar
  24. 24.
    Lamberts R, Creutzfeldt W, Stuber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356–70PubMedGoogle Scholar
  25. 25.
    Brunner G, Arnold R, Henning U, et al. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993; 7 Suppl. 1: 51–5PubMedGoogle Scholar
  26. 26.
    Lind T, Cederberg C, Olausson M, et al. 24-Hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 1990; 99: 1593–8PubMedGoogle Scholar
  27. 27.
    Levant JA, Walsh JH, Isenberg JI. Stimulation of gastric secretion and gastrin release by single oral doses of calcium carbonate in man. N Engl J Med 1973; 289: 555–8PubMedCrossRefGoogle Scholar
  28. 28.
    Higgs RH, Smyth RD, Castell DO. Gastric alkalinization: effect on lower-esophageal spincter pressure and serum gastrin. N Engl J Med 1974; 291: 486–90PubMedCrossRefGoogle Scholar
  29. 29.
    Peters MN, Feldman M, Walsh JH, et al. Effect of gastric alkalinization on serum gastrin concentrations in humans. Gastroenterology 1983; 85: 35–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Yoshihiro Yamamoto
    • 1
  • Shuichi Sezai
    • 1
  • Shin Sakumbayashi
    • 1
  • Masanori Hirano
    • 1
  • Hiroshi Oka
    • 1
  1. 1.Division of GastroenterologyTokyo Metropolitan Police HospitalTokyoJapan

Personalised recommendations